PRINTER'S NO. 2324
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE RESOLUTION
No.
453
Session of
2017
INTRODUCED BY CRUZ, DiGIROLAMO, BAKER, KINSEY, SCHLOSSBERG,
RYAN, TOOHIL, SONNEY, DUSH, MURT, ROZZI, LONGIETTI, READSHAW,
CALTAGIRONE, KORTZ, V. BROWN, WATSON, MILLARD, D. COSTA,
BOBACK, GABLER, SCHWEYER, BIZZARRO, FARRY, GILLEN AND
MARSICO, AUGUST 24, 2017
INTRODUCED AS NONCONTROVERSIAL RESOLUTION UNDER RULE 35,
AUGUST 24, 2017
A RESOLUTION
Designating the month of September 2017 as "Leukodystrophy
Awareness Month" in Pennsylvania.
WHEREAS, Leukodystrophy is a rare and terminal disease
presenting itself in multiple manifestations that attack the
central nervous system, severely impacting physical abilities,
mental capacity and quality of life; and
WHEREAS, The group of rare disorders known as
leukodystrophies destroy the central nervous system by
disrupting the growth and maintenance of myelin, a sheath that
insulates nerve cells and destroys white matter in the brain;
and
WHEREAS, Leukodystrophies are progressive, meaning that they
tend to get worse throughout the life of the patient; and
WHEREAS, There are more than 40 known variations and even
more unidentified forms of leukodystrophy that exist; and
WHEREAS, When all variations of leukodystrophy are grouped
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
together, it is as prevalent as cystic fibrosis; and
WHEREAS, Infants born with leukodystrophy appear normal at
birth, with symptoms appearing during infancy or childhood; and
WHEREAS, There is no cure for leukodystrophy, but treatment
may include medications, physical, occupational and speech
therapies and nutritional, educational and recreational
programs; and
WHEREAS, Additional treatment options such as bone marrow
transplantation are emerging due to continued research and
medical advances; and
WHEREAS, Organizations, including the United Leukodystrophy
Foundation, Hunter's Hope Foundation, the Myelin Project, the
MLD Foundation and the Adrenoleukodystrophy Foundation have
dedicated their work to public education, disease research and
patient treatment; and
WHEREAS, Act 148 of 2014 requires hospitals in this
Commonwealth to screen newborns for Krabbe disease, a
leukodystrophy; and
WHEREAS, X-linked adrenoleukodystrophy (X-ALD) was added to
the Federal Recommended Uniform Screening Panel in 2016; and
WHEREAS, Hospitals in this Commonwealth began screening all
newborns for X-ALD in April 2017; and
WHEREAS, It is imperative that parents learn about
leukodystrophy and understand the importance of screening and
early detection of Krabbe disease, X-ALD and other
leukodystrophies; therefore be it
RESOLVED, That the House of Representatives designate the
month of September 2017 as "Leukodystrophy Awareness Month" in
Pennsylvania; and be it further
RESOLVED, That the Commonwealth officially recognize the
20170HR0453PN2324 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
importance of leukodystrophy awareness and encourage parents and
future parents to educate themselves on these diseases and take
the necessary steps to ensure the health of their children.
20170HR0453PN2324 - 3 -
1
2
3